Companies: 10,795·Total market cap: $144.5T
Silexion Therapeutics Ltd.

Silexion Therapeutics Ltd.

SLXNWNASDAQHealthcare● Active
$0.03
$-0.00(-7.82%)
Market Cap$18512
P/E Ratio
52W High$0.0999
52W Low$0.0272
Overview

Silexion Therapeutics Ltd. (SLXNW) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · SLXNW · as of Jun 8, 2026

Key Statistics

EPS (TTM)slxnw eps ttm · slxnw earnings per shareEarnings history
PE Ratio (TTM)slxnw pe ratio ttm · slxnw price to earningsPE Ratio deep dive
Revenue (TTM)slxnw revenue ttm · slxnw annual revenueFull revenue history
Dividend YieldNo Dividenddoes slxnw pay dividends · slxnw dividend yieldDividend history
Shares Outstandingslxnw shares outstanding · slxnw floatShares outstanding history
Next EarningsTBAslxnw earnings date · slxnw next earningsEarnings history

About Silexion Therapeutics Ltd.

CEOIlan Hadar
IPO DateAug 16, 2024
Employees11
CountryIL

Silexion Therapeutics Ltd. Silexion Therapeutics LTD is a biopharmaceutical company focused on the discovery and development of RNA interference (RNAi)-based therapies and their delivery systems, specifically targeting aggressi…

what is silexion therapeutics ltd. · slxnw stock overview · silexion therapeutics ltd. company profile · who is silexion therapeutics ltd. ceo · slxnw NASDAQ · silexion therapeutics ltd. headquarters · silexion therapeutics ltd. business segments

About Stock Overview & Key Data

Silexion Therapeutics Ltd. (SLXNW) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Aug 16, 2024. As of the latest trading session, SLXNW stock price is $0.03, with a market capitalization of $18,512. The stock has returned — over the past 12 months and — year-to-date.

Frequently Asked Questions

As of the latest trading session, Silexion Therapeutics Ltd. (SLXNW) stock price is $0.03. The stock is traded on NASDAQ under the ticker symbol SLXNW. The 52-week range is $0.03 – $0.10.

SLXNW stock priceSLXNW quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice